Signal Transducer and Activator of Transcription 4-Induced Up-Regulated LINC01278 Enhances Proliferation and Invasion of Non-Small Cell Lung Cancer Cells via the MicroRNA-877-5p/Activating Transcription Factor 4 Axis
Tóm tắt
The purpose of this study was to investigate the specific effects of signal transducer and activator of transcription 4 (STAT4)-induced long intergenic nonprotein coding RNA 1278 (LINC01278) on the growth of non-small cell lung cancer (NSCLC) cells involved in the microRNA (miR)-877-5p/activated transcription factor 4 (ATF4) axis. NSCLC tumor tissue and adjacent normal tissue were collected. Human normal lung epithelial cell BEAS-2B and human NSCLC cell lines (H1299, H1975, A549, H2228) were collected. The expression levels of STAT4, LINC01278, miR-877-5p, and ATF4 were detected. A549 cells were screened for subsequent experiments. The proliferation ability of cells was detected by colony formation experiment. Cell apoptosis was tested by flow cytometry. Scratch test and transwell assay were used to detect the migration and invasion ability of cells. Biological function of LINC01278 in NSCLC was confirmed by xenograft experiments. Low expression miR-877-5p and high expression of STAT4, LINC01278 and ATF4 were detected in NSCLC. Silenced LINC01278 in A549 cell depressed cell proliferation, migration and invasion, but facilitated cell apoptosis. LINC01278 was positively correlated with STAT4 and could directly bind to miR-877-5p. Upregulating miR-877-5p suppressed NSCLC cell progression, while downregulating miR-877-5p had the opposite effect. Upregulating miR-877-5p abrogated the effects of silenced LINC01278 on NSCLC cell progression. MiR-877-5p targeted ATF4. ATF4 upregulation could partly restore the carcinogenic effect of LINC01278 in vitro and in vivo. Our data supports that STAT4-induced upregulation of LINC01278 promotes NSCLC progression by modulating the miR-877-5p/ATF4 axis, suggesting a novel direction for NSCLC treatment.
Từ khóa
Tài liệu tham khảo
Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, et al. Cancer treatment and survivorship statistics. CA Cancer J Clin. 2016;66:271–89.
Jemal A, Siegel R, Xu J, Ward E. Cancer statistics. CA Cancer J Clin. 2010;60:277–300.
Siegel R, Naishadham D, Jemal A. Cancer statistics. CA Cancer J Clin. 2013;63:11–30.
Liao Y, Cao L, Wang F, Pang R. miR-605-5p promotes invasion and proliferation by targeting TNFAIP3 in non-small-cell lung cancer. J Cell Biochem. 2020;121:779–87.
Piipponen M, Nissinen L, Riihilä P, Farshchian M, Kallajoki M, Peltonen J, et al. p53-Regulated Long noncoding RNA PRECSIT promotes progression of cutaneous squamous cell carcinoma via STAT3 signaling. Am J Pathol. 2020;190:503–17.
Tian Y, Ma R, Sun Y, Liu H, Zhang H, Sun Y, et al. SP1-activated long noncoding RNA lncRNA GCMA functions as a competing endogenous RNA to promote tumor metastasis by sponging miR-124 and miR-34a in gastric cancer. Oncogene. 2020;39:4854–68.
An YX, Shang YJ, Xu ZW, Zhang QC, Wang Z, Xuan WX, et al. STAT3-induced long noncoding RNA LINC00668 promotes migration and invasion of non-small cell lung cancer via the miR-193a/KLF7 axis. Biomed Pharmacother. 2019;116:109023.
Huda N, Hosen MI, Yasmin T, Sarkar PK, Hasan A, Nabi A. Genetic variation of the transcription factor GATA3, not STAT4, is associated with the risk of type 2 diabetes in the Bangladeshi population. PLoS ONE. 2018;13: e0198507.
Huang Z, Yu H, Du G, Han L, Huang X, Wu D, et al. Enhancer RNA lnc-CES1-1 inhibits decidual cell migration by interacting with RNA-binding protein FUS and activating PPARγ in URPL. Mol Ther Nucleic Acids. 2021;24:104–12.
Lei L, Xia S, Liu D, Li X, Feng J, Zhu Y, et al. Genome-wide characterization of lncRNAs in acute myeloid leukemia. Brief Bioinform. 2018;19:627–35.
Hu G, Tang Q, Sharma S, Yu F, Escobar TM, Muljo SA, et al. Expression and regulation of intergenic long noncoding RNAs during T cell development and differentiation. Nat Immunol. 2013;14:1190–8.
Iyer MK, Niknafs YS, Malik R, Singhal U, Sahu A, Hosono Y, et al. The landscape of long noncoding RNAs in the human transcriptome. Nat Genet. 2015;47:199–208.
Lin S, Tan L, Luo D, Peng X, Zhu Y, Li H. Linc01278 inhibits the development of papillary thyroid carcinoma by regulating miR-376c-3p/DNM3 axis. Cancer Manag Res. 2019;11:8557–69.
Peng Y, Croce CM. The role of MicroRNAs in human cancer. Signal Transduct Target Ther. 2016;1:15004.
Guo XD, Zhang N, Sha L. MiR-877-5p antagonizes the promoting effect of SP on the gastric cancer progression. Neoplasma. 2020;67:1293–302.
Wang X, Liu L, Zhao W, Li Q, Wang G, Li H. LncRNA SNHG16 promotes the progression of laryngeal squamous cell carcinoma by mediating miR-877-5p/FOXP4 Axis. Onco Targets Ther. 2020;13:4569–79.
Du LJ, Mao LJ, Jing RJ. Long noncoding RNA DNAH17-AS1 promotes tumorigenesis and metastasis of non-small cell lung cancer via regulating miR-877-5p/CCNA2 pathway. Biochem Biophys Res Commun. 2020;533:565–72.
Ma J, Miao H, Zhang H, Ren J, Qu S, Da J, et al. LncRNA GAS5 modulates the progression of non-small cell lung cancer through repressing miR-221-3p and up-regulating IRF2. Diagn Pathol. 2021;16:46.
Meng Q, Li Z, Pan J, Sun X. Long noncoding RNA DUXAP8 regulates proliferation and apoptosis of ovarian cancer cells via targeting miR-590-5p. Hum Cell. 2020;33:1240–51.
Zhang Y, Zhang J, Mao L, Li X. Long noncoding RNA HCG11 inhibited growth and invasion in cervical cancer by sponging miR-942-5p and targeting GFI1. Cancer Med. 2020;9:7062–71.
Wu C, Hu Y, Ning Y, Zhao A, Zhang G, Yan L. Long noncoding RNA plasmacytoma variant translocation 1 regulates cisplatin resistance via miR-3619-5p/TBL1XR1 axis in gastric cancer. Cancer Biother Radiopharm. 2020;35:741–52.
Yu JE, Ju JA, Musacchio N, Mathias TJ, Vitolo MI. Long noncoding RNA DANCR activates Wnt/β-catenin signaling through MiR-216a inhibition in non-small cell lung cancer. Biomolecules. 2020;10:1646.
Wang N, Li J, He J, Jing YG, Zhao WD, Yu WJ, et al. Knockdown of lncRNA CCAT1 inhibits the progression of colorectal cancer via hsa-miR-4679 mediating the downregulation of GNG10. J Immunol Res. 2021;2021:8930813.
Hu RH, Zhang ZT, Wei HX, Ning L, Ai JS, Li WH, et al. LncRNA ST7-AS1, by regulating miR-181b-5p/KPNA4 axis, promotes the malignancy of lung adenocarcinoma. Cancer Cell Int. 2020;20:568.
Xi C, Ye NY, Wang YB. LncRNA LINC01278 accelerates colorectal cancer progression via miR-134-5p/KDM2A axis. Eur Rev Med Pharmacol Sci. 2020;24:10526–34.
Qu Z, Li S. Long noncoding RNA LINC01278 favors the progression of osteosarcoma via modulating miR-133a-3p/PTHR1 signaling. J Cell Physiol. 2020. https://doi.org/10.1002/jcp.29582.
Han Q, Li J, Xiong J, Song Z. Long noncoding RNA LINC00514 accelerates pancreatic cancer progression by acting as a ceRNA of miR-28-5p to upregulate Rap1b expression. J Exp Clin Cancer Res. 2020;39:151.
Wu X, Liu J, Zhu C, Ma M, Chen X, Liu Y, et al. Identification of Potential Biomarkers of Prognosis-Related Long Non-Coding RNA (lncRNA) in Pediatric Rhabdoid Tumor of the Kidney Based on ceRNA Networks. Med Sci Monit. 2020;26:e927725.
Du J, Liu H, Mao X, Qin Y, Fan C. ATF4 promotes lung cancer cell proliferation and invasion partially through regulating Wnt/β-catenin signaling. Int J Med Sci. 2021;18:1442–8.
Schmidt-Hansen M, Baldwin DR, Hasler E. What is the most effective follow-up model for lung cancer patients? A systematic review J Thorac Oncol. 2012;7:821–4.
Gu C, Huang Z, Dai C, Wang Y, Ren Y, She Y, et al. Prognostic analysis of limited resection versus lobectomy in stage IA small cell lung cancer patients based on the surveillance, epidemiology, and end sesults registry database. Front Genet. 2018;9:568.
Li C, Zhang L, Meng G, Wang Q, Lv X, Zhang J, et al. Circular RNAs: pivotal molecular regulators and novel diagnostic and prognostic biomarkers in non-small cell lung cancer. J Cancer Res Clin Oncol. 2019;145:2875–89.
Sun Q, Hao Q, Prasanth KV. Nuclear long noncoding RNAs: key regulators of gene expression. Trends Genet. 2018;34:142–57.
Miklossy G, Hilliard TS, Turkson J. Therapeutic modulators of STAT signalling for human diseases. Nat Rev Drug Discov. 2013;12:611–29.
Zhang YS, Xin DE, Wang Z, Song X, Sun Y, Zou QC, et al. STAT4 activation by leukemia inhibitory factor confers a therapeutic effect on intestinal inflammation. EMBO J. 2019;38: e99595.
Yu H, Jove R. The STATs of cancer–new molecular targets come of age. Nat Rev Cancer. 2004;4:97–105.
Zou XD, Zang Q, Zhang ZZ, Lu YQ, Jin X, Wu Y. Long noncoding RNA ARRDC1-AS1 is activated by STAT1 and exerts oncogenic properties by sponging miR-432-5p/PRMT5 axis in glioma. Biochem Biophys Res Commun. 2021;534:511–8.
Ma L, Shao H, Chen H, Deng Q. The mechanism of miR-141 regulating the proliferation and metastasis of liver cancer cells by targeting STAT4. J Oncol. 2021;2021:5425491.
Hulshoff MS, Del Monte-Nieto G, Kovacic J, Krenning G. Non-coding RNA in endothelial-to-mesenchymal transition. Cardiovasc Res. 2019;115:1716–31.
Matsui M, Corey DR. Non-coding RNAs as drug targets. Nat Rev Drug Discov. 2017;16:167–79.
Huang WJ, Tian XP, Bi SX, Zhang SR, He TS, Song LY, et al. The β-catenin/TCF-4-LINC01278-miR-1258-Smad2/3 axis promotes hepatocellular carcinoma metastasis. Oncogene. 2020;39:4538–50.
Salmena L, Poliseno L, Tay Y, Kats L, Pandolfi PP. A ceRNA hypothesis: the rosetta stone of a hidden RNA language? Cell. 2011;146:353–8.
Shi Q, Xu X, Liu Q, Luo F, Shi J, He X. MicroRNA-877 acts as a tumor suppressor by directly targeting eEF2K in renal cell carcinoma. Oncol Lett. 2016;11:1474–80.
Yan TH, Qiu C, Sun J, Li WH. MiR-877-5p suppresses cell growth, migration and invasion by targeting cyclin dependent kinase 14 and predicts prognosis in hepatocellular carcinoma. Eur Rev Med Pharmacol Sci. 2018;22:3038–46.
Li S, Zhu Y, Liang Z, Wang X, Meng S, Xu X, et al. Up-regulation of p16 by miR-877-3p inhibits proliferation of bladder cancer. Oncotarget. 2016;7:51773–83.
Wang T, Li LY, Chen YF, Fu SW, Wu ZW, Du BB, et al. Ribosome assembly factor URB1 contributes to colorectal cancer proliferation through transcriptional activation of ATF4. Cancer Sci. 2021;112:101–16.
Liu J, Qi YB. Activation of LXRβ inhibits proliferation, promotes apoptosis, and increases chemosensitivity of gastric cancer cells by upregulating the expression of ATF4. J Cell Biochem. 2019;120:14336–47.
Linares JF, Cordes T, Duran A, Reina-Campos M, Valencia T, Ahn CS, et al. ATF4-induced metabolic reprograming is a synthetic vulnerability of the p62-deficient tumor stroma. Cell Metab. 2017;26:817-29.e6.
Yang X, Xia R, Yue C, Zhai W, Du W, Yang Q, et al. ATF4 regulates CD4(+) T cell immune responses through metabolic reprogramming. Cell Rep. 2018;23:1754–66.
Yoshizawa T, Hinoi E, Jung DY, Kajimura D, Ferron M, Seo J, et al. The transcription factor ATF4 regulates glucose metabolism in mice through its expression in osteoblasts. J Clin Invest. 2009;119:2807–17.